Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Yoshiya TanakaTsutomu TakeuchiHisashi YamanakaToshihiro NankiHisanori UmeharaNobuyuki YasudaFumitoshi TagoYasumi KitaharaMakoto KawakuboKentaro ToriiSeiichiro HojoTetsu KawanoToshio ImaiPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
This is the first evidence that E6011, a novel cell trafficking inhibitor targeting the FKN-CX3 CR1 interaction, is modestly effective with 24 weeks of treatment in RA patients, although the primary end point was not met.
Keyphrases
- placebo controlled
- phase ii study
- rheumatoid arthritis
- double blind
- monoclonal antibody
- end stage renal disease
- ejection fraction
- open label
- newly diagnosed
- disease activity
- study protocol
- clinical trial
- phase ii
- chronic kidney disease
- prognostic factors
- phase iii
- high dose
- cell therapy
- low dose
- stem cells
- ankylosing spondylitis
- systemic lupus erythematosus
- interstitial lung disease
- mesenchymal stem cells
- drug delivery
- patient reported outcomes
- combination therapy
- systemic sclerosis
- rectal cancer